Rare Disease Diagnostics Market By Type (Hematology & Oncology) By Applications (Genetic Testing Laboratories, Cancer Research Laboratories, Others), Regional Analysis & Forecast - 2024
- OI-57 |
- Published date: Jan, 2019 |
- Biopharmaceuticals |
- Pages
Often rare diseases are chronic and life-threatening. Rare diseases can be single gene, multifactorial, chromosomal or non-genetic.
Scope of the Report:
The global Rare Disease Diagnostics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Rare Disease Diagnostics.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Rare Disease Diagnostics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Rare Disease Diagnostics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Retrophin
3billion
23andMe
QIAGEN
Illumina
PerkinElmer
Strand Life Sciences
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hematology
Oncology
Market Segment by Applications, can be divided into
Hospital Laboratories
Diagnostic Laboratories
Genetic Testing Laboratories
Cancer Research Laboratories
Others
Often rare diseases are chronic and life-threatening. Rare diseases can be single gene, multifactorial, chromosomal or non-genetic.
Scope of the Report:
The global Rare Disease Diagnostics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Rare Disease Diagnostics.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Rare Disease Diagnostics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Rare Disease Diagnostics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Retrophin
3billion
23andMe
QIAGEN
Illumina
PerkinElmer
Strand Life Sciences
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Hematology
Oncology
Market Segment by Applications, can be divided into
Hospital Laboratories
Diagnostic Laboratories
Genetic Testing Laboratories
Cancer Research Laboratories
Others
-
Data Collation (Primary & Secondary)
-
In-house Estimation (Based on proprietary databases and Models)
-
Market Triangulation
-
Forecasting
-
Market-related information is assembled from both primary and secondary sources.
-
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
-
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
-
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
